Magnesium outside nerve cells helps prevent brain damage during injury by keeping NMDA receptors from opening too much, which stops excessive calcium from entering and killing neurons.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether magnesium sulfate improves neurological outcomes in humans with acute traumatic brain injury or ischemic stroke by reducing NMDAR-mediated excitotoxicity.
A systematic review and meta-analysis of all randomized controlled trials in adults with moderate-severe TBI or ischemic stroke comparing IV magnesium sulfate (1–2 g/h for 24–48 h) versus placebo, with primary outcomes: 90-day GOS-E score, mortality, and serum biomarkers of excitotoxicity (glutamate, S100B).
Whether IV magnesium reduces NMDAR-mediated excitotoxicity in humans with acute ischemic stroke, measured by neuroimaging and biomarkers.
A double-blind RCT of 200 adults with acute ischemic stroke (onset <3 h), randomized to IV magnesium sulfate (1.5 g/h for 24 h) or saline, with primary outcomes: change in diffusion-weighted MRI lesion volume, serum glutamate, and 90-day mRS score.
Whether low serum magnesium predicts worse neurological outcomes after traumatic brain injury in humans.
A prospective cohort of 500 adults with moderate-severe TBI, measuring serum magnesium within 6 h of injury and following for 6 months with serial GOS-E scores, adjusting for age, injury severity, and hypotension.
Whether patients with post-traumatic epilepsy have lower cerebrospinal fluid magnesium compared to TBI patients without seizures.
A case-control study comparing CSF magnesium levels in 40 TBI patients who developed post-traumatic epilepsy and 40 matched TBI patients without seizures, measured via lumbar puncture at 3 months post-injury.
Whether serum magnesium correlates with cortical excitability in healthy adults, measured by TMS and NMDAR pharmacology.
A cross-sectional study of 200 healthy adults, measuring serum magnesium and cortical excitability via TMS (SICI and ICF), with and without intravenous ketamine (NMDAR blocker), adjusting for age, sex, and renal function.